drugset

drugset / Trial / NCT01114490

Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

NCT01114490 ↗

Phase 1 Completed 24 enrolled Merck Sharp & Dohme LLC

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib.

Timeline

Start: 2010-05
Primary completion: 2010-07
Completion: 2010-07

Publications

Results Lauring B, Li XS, Liu Y, Corr C, Lazarus N, Cote J, Larson P, Levonas AO, Lasseter KC, Preston RA, Smith WB, Lai E, Wagner JA. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. J Clin Pharmacol. 2014 Nov;54(11):1247-55. doi: 10.1002/jcph.320. Epub 2014 Jun 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anacetrapib	Small molecule	100 mg	Oral

Indications